45 articles - From Friday Aug 12 2022 to Friday Aug 19 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Ann Intern Med |
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Recommendation 5 (prophylaxis) The AABB suggests against prophylactic CCP transfusion for uninfected persons with close contact exposure to a person with COVID-19 (weak recommendation, low-certainty evidence). Good clinical practice statement CCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Intern Med |
Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Although LAAO could be an alternative to anticoagulants for stroke prevention in patients with AF and high bleeding risk, the overall benefit from LAAO depends on the combination of stroke and bleeding risks in individual patients. These results suggest the need for a sufficiently low stroke risk for LAAO to be beneficial. The authors believe that these results could improve shared decision making when selecting patients for LAAO. Primary funding source None. |
| Lancet |
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lesion swabs showed the highest viral loads, which, combined with the history of sexual exposure and the distribution of lesions, suggests close contact is probably the dominant transmission route in the current outbreak. Funding None. |
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Interpretation Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic asthma reduced the number of exacerbations. Funding US National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. |
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent a-thalassaemia or ß-thalassaemia: an open-label, multicentre, phase 2 study. Interpretation These efficacy and safety results support the continued investigation of mitapivat for the treatment of both a-thalassaemia and ß-thalassaemia. Funding Agios Pharmaceuticals. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Lancet |
Interstitial lung diseases. Furthermore, we describe how developments have led to a shift in the classification and treatment of interstitial lung diseases that exhibit progressive pulmonary fibrosis and summarise the latest practice-changing guidelines. We conclude with an outline of controversies, uncertainties, and future directions. |
Letters to the editors and authors’ replies
| Lancet |
all remaining publications eg case reports, images of the month, etc…
| Ann Intern Med |
| Lancet |
| N Engl J Med |